3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
7
Fallopian Tube Neoplasms
6
Breast Neoplasms
6
Neoplasms
4
Sarcoma
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Multi-centric Castleman's Disease
2
Lymphoma, B-Cell
2
Sarcoma, Kaposi
1
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Primary Effusion
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, AIDS-Related
1
Lymphoma
1
Lymphadenopathy
1
Lung Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Kidney Neoplasms
1
Invasive Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
HIV Infections
1
Glioma
1
Fallopian Tube Mucinous Adenocarcinoma
1
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
liposomal doxorubicin
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled